EXPLORing the Therapeutic Ceiling in Crohn ’s Disease: Will Combination Pave the Way?

There are numerous synonyms for explorer including: adventurer, pathfinder, pioneer, seeker, experimenter, pilgrim, searcher, and traveler. The investigators in the EXPLORER trial sought to improve the “efficacy ceiling” for treating Crohn’s disease (CD) by venturing into combination therapy by combining 3 semi-independent mechanisms of action (MOAs) that, individually, have demonstrable efficacy.1 Both vedolizumab and adalimumab are biological drugs approved to induce and maintain remission , whereas (parenteral) methotrexate has not been evaluated as an independent induction agent.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research